PTCT

MKT CAP:$6B

PTC Therapeutics, Inc.

Market Cap

$6B

Healthcare·Biotechnology·🇺🇸 United States·NASDAQ

Healthcare·Biotechnology·🇺🇸·NASDAQ

Stock Price

$70.85-$5.89 (-7.68%)

Apr 22, 2026

Company Details

PTC Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of medicines to patients with rare disorders. Its portfolio pipeline includes commercial products and product candidates in va...

CEO

Matthew Klein

IPO Date

Jun 20, 2013

Website

www.ptcbio.com

Key Metrics TTM

Revenue

$1.7B

+114.5% YoY

Net Income

$683M

EPS (Diluted)

$7.74

Free Cash Flow

$699M

Revenue / Share

$21.45

Gross Margin

91.0%

Operating Margin

49.5%

Net Margin

39.4%

FCF Margin

40.4%

P/S

3.3x

P/E

8.3x

Earnings Reports

Q1 2026

May 5, 2026

PENDING

FY 2025

Feb 19, 2026

$1.7B+114.5%EPS $7.78

Q4 2025

Feb 19, 2026

$165M-22.7%EPS -$1.67

Q3 2025

Nov 4, 2025

$211M+7.2%EPS $0.20

Q2 2025

Aug 7, 2025

$179M-4.2%EPS -$0.83

Revenue & Profitability

Quarter	Revenue	Gross Profit	Operating Income
Q1 22	$149M	$139M	-$87M
Q2 22	$166M	$156M	-$92M
Q3 22	$217M	$203M	-$73M
Q4 22	$167M	$157M	-$200M
Q1 23	$220M	$206M	-$118M
Q2 23	$214M	$201M	-$210M
Q3 23	$197M	$187M	-$118M
Q4 23	$307M	$201M	$3M
Q1 24	$210M	$195M	-$45M
Q2 24	$187M	$171M	-$40M
Q3 24	$197M	$186M	-$55M
Q4 24	$213M	$197M	-$162M
Q1 25	$1.2B	$1.2B	$970M
Q2 25	$179M	$167M	-$35M
Q3 25	$211M	$95M	$3M
Q4 25	$165M	$148M	-$82M

Valuation

Quarter	P/S	P/E
Q1 22	4.5x	—
Q2 22	4.6x	—
Q3 22	5.3x	—
Q4 22	4.4x	—
Q1 23	4.6x	—
Q2 23	3.8x	—
Q3 23	2.0x	—
Q4 23	2.4x	—
Q1 24	2.3x	—
Q2 24	2.6x	—
Q3 24	3.2x	—
Q4 24	4.4x	—
Q1 25	2.2x	6.6x
Q2 25	2.2x	6.1x
Q3 25	2.7x	6.3x
Q4 25	3.7x	9.3x

Operating Cash Flow

Quarter	Operating CF	Free CF
Q1 22	-$97M	-$179M
Q2 22	-$55M	-$73M
Q3 22	-$38M	-$64M
Q4 22	-$166M	-$193M
Q1 23	-$29M	-$73M
Q2 23	-$14M	-$33M
Q3 23	-$15M	-$44M
Q4 23	-$100M	-$129M
Q1 24	$71M	$6M
Q2 24	-$71M	-$64M
Q3 24	-$77M	-$88M
Q4 24	-$30M	-$37M
Q1 25	$870M	$868M
Q2 25	-$58M	-$62M
Q3 25	-$66M	-$70M
Q4 25	-$34M	-$37M

Capital Expenditures

Quarter	CapEx
Q1 22	$81M
Q2 22	$18M
Q3 22	$26M
Q4 22	$27M
Q1 23	$44M
Q2 23	$19M
Q3 23	$29M
Q4 23	$28M
Q1 24	$64M
Q2 24	$7M
Q3 24	$11M
Q4 24	$6M
Q1 25	$3M
Q2 25	$4M
Q3 25	$3M
Q4 25	$2M

CapEx

OpEx vs Revenue Growth (YoY)

Quarter	Revenue Growth	OpEx Growth
Q1 22	+26.1%	+8.9%
Q2 22	+41.9%	+19.9%
Q3 22	+56.5%	+25.4%
Q4 22	+1.3%	+47.1%
Q1 23	+48.2%	+43.7%
Q2 23	+29.2%	+64.2%
Q3 23	-9.5%	+8.3%
Q4 23	+83.4%	-17.4%
Q1 24	-4.7%	-24.4%
Q2 24	-12.7%	-46.4%
Q3 24	+0.1%	-20.2%
Q4 24	-30.6%	+23.6%
Q1 25	+459.7%	-19.4%
Q2 25	-4.2%	-5.8%
Q3 25	+7.2%	-17.2%
Q4 25	-22.7%	-34.4%

Stock-Based Compensation

Quarter	SBC ($)	% of Revenue
Q1 22	$27M	17.9%
Q2 22	$28M	16.8%
Q3 22	$29M	13.2%
Q4 22	$27M	16.3%
Q1 23	$29M	13.1%
Q2 23	$59M	27.6%
Q3 23	$27M	13.7%
Q4 23	$17M	5.4%
Q1 24	$18M	8.7%
Q2 24	$19M	10.3%
Q3 24	$20M	10.0%
Q4 24	$17M	8.1%
Q1 25	$18M	1.5%
Q2 25	$19M	10.4%
Q3 25	$19M	9.2%
Q4 25	$0	0.0%

OpEx Breakdown

Quarter	R&D	G&A	SG&A
Q1 22	$140M	—	$73M
Q2 22	$157M	—	$80M
Q3 22	$165M	$80M	—
Q4 22	$189M	—	$93M
Q1 23	$195M	—	$87M
Q2 23	$186M	—	$88M
Q3 23	$164M	$81M	—
Q4 23	$121M	$81M	—
Q1 24	$116M	—	$73M
Q2 24	$132M	—	$70M
Q3 24	$161M	—	$73M
Q4 24	$125M	—	$85M
Q1 25	$109M	—	$81M
Q2 25	$113M	—	$85M
Q3 25	$100M	—	$84M
Q4 25	$133M	—	$100M

Revenue Segments

Quarter	Manufacturing	Product	Royalty	Collaboration and License Revenue
Q2 24	$800.0K	$133M	$53M	—
Q3 24	$800.0K	$135M	$61M	—
Q1 25	—	$153M	$36M	$986M
Q2 25	—	$118M	$58M	$3M
Q3 25	—	$131M	$71M	$9M

War Chest

Quarter	Cash	Short-term Investments	Total
Q1 22	$144M	$444M	$588M
Q2 22	$158M	$347M	$506M
Q3 22	$104M	$184M	$288M
Q4 22	$280M	$131M	$411M
Q1 23	$167M	$119M	$286M
Q2 23	$208M	$130M	$338M
Q3 23	$165M	$130M	$295M
Q4 23	$594M	$283M	$877M
Q1 24	$548M	$336M	$885M
Q2 24	$655M	$439M	$1.1B
Q3 24	$526M	$487M	$1.0B
Q4 24	$780M	$360M	$1.1B
Q1 25	$1.5B	$547M	$2.0B
Q2 25	$1.0B	$972M	$2.0B
Q3 25	$673M	$1.0B	$1.7B
Q4 25	$985M	$961M	$1.9B

Shares Outstanding

Quarter	Shares (Diluted)	QoQ Change	YoY Change
Q1 22	71M	+0.8%	+1.5%
Q2 22	71M	+0.2%	+1.4%
Q3 22	72M	+0.4%	+1.5%
Q4 22	73M	+1.4%	+2.8%
Q1 23	74M	+1.5%	+3.5%
Q2 23	75M	+1.4%	+4.7%
Q3 23	75M	+0.9%	+5.2%
Q4 23	76M	+0.2%	+3.9%
Q1 24	76M	+1.3%	+3.8%
Q2 24	77M	+0.3%	+2.7%
Q3 24	77M	+0.3%	+2.1%
Q4 24	77M	+0.4%	+2.2%
Q1 25	86M	+11.9%	+12.9%
Q2 25	78M	-9.5%	+1.9%
Q3 25	87M	+11.5%	+13.2%
Q4 25	81M	-7.4%	+4.5%

Shares Outstanding

Revenue Per Employee

Period	Revenue/Employee	Employees
Q1 22	$126.4K	1K
Q2 22	$140.6K	1K
Q3 22	$184.5K	1K
Q4 22	$118.7K	1K
Q1 23	$156.3K	1K
Q2 23	$151.6K	1K
Q3 23	$139.4K	1K
Q4 23	$308.6K	995
Q1 24	$211.2K	995
Q2 24	$187.6K	995
Q3 24	$197.8K	995
Q4 24	$213.2K	1K
Q1 25	$1M	1K
Q2 25	$178.9K	1K
Q3 25	$211.0K	1K
Q4 25	$2.8K	58K

Revenue / Employee